低用量アスピリン・NSAIDs潰瘍対策ハンドブック

出版社: 先端医学社
著者:
発行日: 2011-09-30
分野: 臨床医学:内科  >  消化器一般
ISBN: 9784884077457
電子書籍版: 2011-09-30 (第1版第2刷)
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

3,080 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,540 円(税込)

商品紹介

臨床医がLDA(低用量アスピリン)とNSAIDs(非ステロイド性抗炎症薬)の潰瘍リスクを知り、それによって引き起こされる問題をよく理解し、適切な対応を実践する手助けとなるハンドブック。

目次

  • 低用量アスピリン・NSAIDs潰瘍対策ハンドブック

    ―目次―

    PART 1 わが国のNSAIDs潰瘍の実態から治療および予防の意義を知る
     1.NSAIDs潰瘍の発症頻度をみる
     2.NSAIDs潰瘍が原疾患に与える影響をみる
     3.NSAIDs潰瘍の臨床的問題の重大性をみる

    PART 2 NSAIDsによるその他の消化管への影響を知る
     1.低用量アスピリンによる食道への影響をみる
     2.NSAIDsによる小腸・大腸への影響をみる

    PART 3 NSAIDs潰瘍の治療の実際を知る
     NSAIDs潰瘍治療の実際とH.pyloriとNSAIDs潰瘍の関係を探る

    PART 4 NSAIDs潰瘍の予防の実際を知る
     NSAIDs潰瘍の一次予防・二次予防をみる

    PART 5 NSAIDs潰瘍の保険診療と実地診療のためのQ&A
     1.保険診療に関するQ&A
     2.循環器、脳領域に関するQ&A
     3.整形外科領域に関するQ&A

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1. わが国のNSAIDs潰瘍の実態から治療および予防の意義を知る

P.24 掲載の参考文献
1) Antiplatelet Trialists' Collaboration:Collaborative overview of randomized trials of antiplatelet therapy-I:prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994
2) Muir A, Cossar IA:Aspirin and ulcer. Br Med J 2:7-12, 1955
3) Douthwaite AH, Lond MD, Lintotto GAM:Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 232:1222-1224, 1938
4) 森本正好:「アスピリン」胃潰瘍の一例. 診断と治療 21:1044-1045, 1934
5) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer disease:a meta-analysis. Lancet 359:14-22, 2002
6) Sakamoto C, Sugano K, Ota S et al:Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62:765-772, 2006
7) 塩川優一, 延永正, 斎藤輝信ほか:非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31:96-111, 1991
8) Rostom A, Dube C, Wells GA et al:Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev, 4:CDOO2296, 2002 (Review content assessed as up-to-date:11May 2009)
9) Yeomans ND, Lanas AI, Talley NJ et al:Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795-801, 2005
10) Taha AS, McCloskey C, Prasad R et al:Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS):a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374:119-125, 2009
11) Scheiman JM, Devereaux PJ, Herlitz J et al:Prevention of peptic ulcers with esomeprazole in patients at risk for ulcer development treated with low-dose acetylsalicylic acid:a randomised, controlled trial (OBERON). Heart, published online March 17, 2011
12) Sugano K, Matsumoto Y, Itabashi T et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 46:724-735, 2011
13) Derry S, Loke YK:Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis. BMJ 321:1183-1187, 2000
14) Cryer B, Feldman M:Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117:17-25, 1999
15) MacDonald TM, Morant SV, Goldstein JL et al:Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52:1265-1270, 2003
16) Singh G, Fort JG, Goldstein JL et al:Celecoxib versus naproxen and diclofenac in osteoarthritis patients:SUCCESS-I Study Am J Med 119:255-266, 2006
17) Kelly JP, Kaufman DW, Jurgelon JM et al:Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348:1413-1416,1996
18) Petroski D:Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 15:314-320, 1993
19) Wolfe MM, Lichtenstein DR, Singh G:Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899, 1999
20) EBMに基づく胃潰瘍診療ガイドライン第2版, 胃潰瘍診療ガイドラインの適用と評価に関する研究班, じほう, 東京, 2007, pp. 101-110
21) Lanza FL, Chan FK, Quigley EM:Practice parameters committee of the American college of gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728-738, 2009
22) Lanas A, Scheiman J:Low-dose aspirin and upper gastrointestinal damage:epidemiology, prevention and treatment. Curr Med Res Opin 23:163-173, 2007
23) Bhatt DL, Scheiman J, Abraham NS et al:ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 103:2890-2907, 2008
24) Chan FK, Chung SC, Suen BY et al:Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973, 2001
25) Fletcher EH, Johnston DE, Fisher CR et al:Systematic review:Helicobacter Pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 32:831-839, 2010
26) Charlot M, Grove EL, Hansen PR et al:Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction:nationwide propensity score matched study. BMJ 342:d2690, 2011
P.41 掲載の参考文献
2) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版), 日本循環器学会ほか;2008年度合同研究班, 2009
3) 脳卒中治療ガイドライン2009, 脳卒中合同ガイドライン委員会, 協和企画, 東京, 2009
4) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet 348:1329-1339, 1996
5) Teramoto T, Shimada K, Uchiyama S et al:Rationale, design, and baseline data of the Japanese primary prevention project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J 159:361-369, e4, 2010
6) 急性心筋梗塞(ST上昇型)の診療に関するガイドライン, 日本循環器学会ほか;2006-2007年度合同研究班. Circulation Journal 72:1347-1442, 2008
7) 急性冠症候群の診療に関するガイドライン(2007年改訂版), 日本循環器学会ほか;2006年度合同研究班, 2007
8) Juul-Moller S, Edvardsson N, Jahnmatz B et al:Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish angina pectoris aspirin trial (SAPAT) Group. Lancet 340:1421-1425, 1992
9) 科学的根拠に基づく糖尿病診療ガイドライン改訂第2版, 日本糖尿病学会, 南江堂, 東京, 2007
10) Ogawa H, Nakayama M, Morimoto T et al:Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes:a randomized controlled trial. JAMA 300:2134-2141, 2008
11) 末梢閉塞性動脈疾患の治療ガイドライン, 日本循環器学会ほか;2005-2008年度合同研究班. Circulation Journal 73(Suppl 3):1507-1558, 2009
12) Maulaz AB, Bezerra DC, Michel P et al:Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62:1217-1220, 2005
13) Sibon I, Orgogozo JM:Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 62:1187-1189, 2004
14) Biondi-Zoccai GG, Lotrionte M, Agostoni P et al:A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27:2667-2674, 2006
15) Kimura T, Morimoto T, Nakagawa Y et al:Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119:987-995, 2009
17) O'Donnell MJ, Kapral MK, Fang J et al:Gastrointestinal bleeding after acute ischemic stroke. Neurology 71:650-655, 2008
18) Manoukian SV, Feit F, Mehran R et al:Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes:an analysis from the ACUITY trial. J Am Coll Cardiol 49:1362-1368, 2007
19) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use:A report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation 118:1894-1909, 2008
20) Yamamoto T, Isono A, Mishina Y et al:Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs:possible effect of rebamipide. J Clin Biochem Nutr 47:27-31, 2010
P.53 掲載の参考文献
1) 大石了三:痛みの種類と鎮痛薬. 臨牀と研究 84:762-765, 2007
2) 川合眞一:非ステロイド抗炎症薬, 鎮痛・解熱薬, 総合感冒薬. 今日の治療薬2009, 水島裕編, 南江堂, 東京, 2009, pp. 267-275
3) Sakamoto C, Soen S:Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion 83:108-123, 2011
4) Zhang W, Moskowitz RW, Nuki G et al:OARSI recommendations for the management of hip and knee osteoarthritis. I. Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15:981-1000, 2007
5) Louthrenoo W, Nilganuwong S, Aksaranugraha S et al:The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis:a randomized, double-blind, NSAID-controlled study. Osteoarthritis Cartilage 15:605-614, 2007
P.61 掲載の参考文献
1) EBMに基づく胃潰瘍診療ガイドライン第2版, 胃潰瘍ガイドラインの適用と評価に関する研究班編, じほう, 東京, 2007
3) Taha AS, Angerson WJ, Knill-Jones RP et al:Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs-a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 22:285-289, 2005
4) 溝上裕士, 岩本淳一:非ステロイド性抗炎症薬による上部消化管障害-その治療と予防-. Medical Practice 26:775-779, 2009
5) 岩本淳一, 溝上裕士:低用量アスピリンによる胃粘膜傷害の実態. Helicobacter Research 13:98-104, 2009
6) Yeomans ND, Lanas AI, Talley NJ et al:Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795-801, 2005
7) Niv Y, Battler A, Abuksis G et al:Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 50:78-80, 2005
8) Iwamoto J, Mizokami Y, Shimokobe K et al:Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin. Dig Dis Sci 55:2270-2274, 2010
9) 消化性潰瘍診療ガイドライン, 日本消化器病学会, 南江堂, 東京, 2009
10) Hooper L, Brown TJ, Elliott R et al:The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs:systematic review. BMJ 329:948, 2004
11) Hawkey CJ, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 338:727-734, 1998
12) Graham DY, Agrawal NM, Lukasik NL et al:NSAID-associated gastric ulcer prevention study group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs:results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162:169-175, 2002
13) Goldstein JL, Huang B, Amer F et al:Ulcer recurrence in high risk patients receiving nonsteroidal anti-inflammatory drugs plus low dose aspirin:results of a post HOC subanalysis. Clin Ther 26:1637-1643, 2004

PART 2. NSAIDsによるその他の消化管への影響を知る

P.74 掲載の参考文献
1) Lanas A, Hirschowitz BI:Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol 13:622-627, 1991
2) Taha AS, Angerson WJ, Knill-Jones RP et al:Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapy. Aliment Pharmacol Ther 23:489-495, 2006
3) Taha AS, Angerson WJ, Morran CG:Correlation between erosive oesophagitis and gastro-duodenal diseases, the influence of aspirin, simple analgeisics, and Helicobacter pylori. Eur J Gastroenterol Hepatol 14:1313-1317, 2002
4) Avidan B, Sonnenberg A, Schnell TG et al:Risk factors for erosive reflex esophagitis;a case-control study. Am J Gastroenterol 96:41-46, 2001
5) Yeomans N, Lanas A, Labenz J et al:Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103:2465-2473, 2008
6) Yamamoto T et al:Characteristics of erosive esophagitis in patients taking low-dose aspirin. Digestion 79 (suppl 1):53-77, 2009
7) Kawai T, Yamagishi T, Goto S:Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period. J Atheroscler Thromb 16:155-163, 2009
8) Kawai T, Watanabe M, Yamashina A:Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy:Preliminary study. J Gastroenterol Hepatol 25 (Suppl 1):S23-S30, 2010
9) Bhatt DL, Scheiman J, Abraham NS et al, American college of cardiology foundation task force on clinical expert consensus documents circulation:ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use:a report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol 52:1502-1517, 2008
10) Yeomans ND, Lanas AI, Taley NJ et al:Prevalance and incidence of gastroduodenal ulcers during treatment with vascular protective doses aspirin. Aliment Pharmacol Ther 22:795-801, 2005
11) 胃食道逆流症 (GERD) 診療ガイドライン, 日本消化器病学会編, 南江堂, 東京, 2009
12) Nguyen DM, El-Serag HB, Henderson L et al:Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 7:1299-1304, 2009
13) Kinoshita Y, Kawanami C, Kishi K et al:Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 41:452-458, 1997
P.86 掲載の参考文献
1) EBMに基づく胃潰瘍診療ガイドライン第2版, 胃潰瘍ガイドラインの適用と評価に関する研究班編, じほう, 東京, 2007
2) Higuchi K, Umegaki E, Watanabe T et al:Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 44:879-888, 2009
3) Takeuchi K, Miyazawa T, Tanaka A et al:Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 66:30-41, 2002
4) 菅野健太郎:NSAIDと消化管障害. 日消誌 106:321-326, 2009
5) Watanabe T, Higuchi K, Kobata A et al:Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57:181-187, 2008
6) 蔵原晃一, 松本主之, 飯田三雄ほか:NSAID起因性大腸病変の臨床像と内視鏡像. 胃と腸 42:1739-1749, 2007
7) Allison MC, Howatson AG, Torrance CJ et al:Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327:749-754, 1992
8) Graham DY, Opekun AR, Willingham FF et al:Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 3:55-59, 2005
9) Amano Y, Kushiyama Y, Takahashi Y et al:Prevalence of ileo-colonic ulcerative lesions in Chronic NSAIDs users. Am J Gastroenterol 99:1193, 2004
10) 村野実之, 柿本一城, 依田有紀子ほか:高齢者におけるNSAIDs下部消化管病変の特徴. 老年消化器病 21:13-17, 2009
11) 松本主之, 飯田三雄, 蔵原晃一ほか:NSAID起因性下部消化管病変の臨床像. 胃と腸 35:1147-1158, 2000
12) 富安信夫, 鶴田修, 光川慶一ほか:薬剤性出血性腸炎. 胃と腸 40:611-615, 2005
13) Watanabe T, Sugimori S, Kameda N et al:Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol:a pilot study. Clin Gastroenterol Hepatol 6:1279-1282, 2008
14) Umegaki E, Morita E, Nouda S et al:Geranylgeranylacetone protects against NSAIDs-induced gastric and small intestinal mucosal injuries in healthy subjects:A prospective randomised study compared with famotidine. Gastrointest Endosc 71:AB363, 2010
15) Kuramoto T, Umegaki E, Kojima Y et al:Irsogladine, a gastroprotective drug, protects against NSAID-induced esophagitis, peptic ulcers, and small intestinal mucosal damages in healthy subjects:A prospective randomised study of comparison with omeprazole. Gastrointest Endosc 73:AB445, 2011
16) Umegaki E, Yoda Y, Tokioka S et al:Protective effect of roxatidine against indomethacin induced small intestinal mucosal injury in rats. J Gastroenterol Hepatol 25:S35-S40, 2010
17) Yoda Y, Takeuchi K, Kato S et al:Search for prophylactic drugs against NSAID-induced small intestinal lesions in rats. Gastroenterology l34:A528, 2008

PART 3. NSAIDs潰瘍の治療の実際を知る

P.101 掲載の参考文献
1) EBMに基づく胃潰瘍診療ガイドライン第2版. 胃潰瘍ガイドラインの適用と評価に関する研究班, じほう, 東京, 2007
2) 消化性潰瘍診療ガイドライン, 日本消化器病学会編, 南江堂, 東京, 2009
3) Tildesley G, Ehsanullah RS, Wood JR:Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drugs. Br J Rheumatol 32;474-478, 1993
4) Jaszewski R, Graham DY, Stromatt SC:Treatment of nonsteroidal antiinflammatory drug-induced gastric ulcers with misoprostol. A double-blind multicenter study. Dig Dis Sci 37:1820-1824, 1992
5) Sontag SJ, Schnell TG, Budiman-Mak E et al:Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil). Am J Gastroenterol 89:1014-1020, 1994
7) Bianchi Porro G, Lazzaroni M, Manzionna G et al:Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 12:355-360, 1998
8) Manniche C, Malchow-Moller A, Andersen JR et al:Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut 28:226-229, 1987
9) 0'Laughlin C, Silvoso GK, Ivey KJ:Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up. Dig Dis Sci 27:976-980, 1982
10) Wu CS, Wang SH, Chen PC et al:Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy? Int J Clin Pract 52:472-474, 1998
11) Nema H, Kato M:Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol 42:5342-5346, 2010
12) Hawkey CJ, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management(OMNIUM) study group. N Engl J Med 338:727-734, 1998
13) Yeomans ND, Tulassay Z, Juhasz L et al:A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial:Ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med 338:719-726, 1998
14) Agrawal NM, Campbell DR, Safdi MA et al:Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers:results of a double-blind, randomized, multicenter study. NSAID-associated gastric ulcer study group. Arch Intern Med 160:1455-1461, 2000
15) Campbell DR, Haber MM, Sheldon E et al:Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 97:2208-2214, 2002
16) Goldstein JL, Johanson JF, Hawkey CJ et al:Clinical trial:healing of NSAID- associated gastric ulcers in patients continuing NSAID therapy- a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 26:1101-1111, 2007
17) 加藤元嗣, 清水勇一, 鄭日男ほか:除菌後の長期経過. 日本臨牀 63 (Suppl 11):491-494, 2005
18) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease. A meta-analysis. Lancet 359:14-22, 2002
19) Porro BG, Parente F, Imbesi V et al:Role of Helicobacter pylori in ulcer healing anr recurrence of gastric and duodenal ulcers in longterm NSAID users:response to omeprazole dual therapy. Gut 39:22-26, 1996
20) Hawkey CJ, Tulassay Z, Szczepanski L et al:Randomised controlled trial of Helicobacter Pylori eradication in patients on non-steroidal anti-inflammatory drugs:HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 352:1016-1021, 1998
21) Chan FK, Sung JJ, Suen R et al:Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study Aliment Pharmacol Ther 12:1201-1205, 1998
22) 加藤元嗣, 小野尚子, 間部克裕ほか:NSAIDs潰瘍におけるH. Pylori除菌の意義. 日本臨牀 69:1049-1056, 2011
23) Nishikawa K, Sugiyama T, Kato M et al:Non-Helicobacter pylori and non-NSAID peptic ulcer disease inthe Japanese population. Eur J Gastroenterol Hepatol l2:635-640, 2000

PART 4. NSAIDs潰瘍の予防の実際を知る

P.115 掲載の参考文献
1) Yeomans N, Wilson I, Langstrom G et al:Quality of life in chronic NSAID users:a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 30:328-334, 2001
2) Taha AS, Hudson N, Hawkey CJ et al:Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435-1439, 1996
3) Levine LR, Cloud ML, Enas NH:Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 153:2449-2454, 1993
4) Desai JC, Sanyal SM, Goo T et al:Primary prevention of adverse gastroduodenal effects from short-term use of nonsteroidal anti-inflammatory drugs by omeprazole 20mg in healthy subjects:a randomized, double-blind, placebo-controlled study. Dig Dis Sci 53:2059-2065, 2008
5) Bianchi Porro G, Lazzaroni M, Petrillo M et al:Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. ltal J Gastroenterol Hepatol 30:43-47, 1998
6) Taha AS, McCloskey C, Prasad R et al:Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS):a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374:119-125, 2009
7) Yeomans N, Lanas A, Labenz J et al:Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103:2465-2473, 2008
8) Hawkey CJ, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management(OMNIUM)study group. N Engl J Med 338:727-734, 1998
9) Yeomans ND, Tulassay Z, Juhasz L et al:A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial:ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med 338:719-726, 1998
10) Lanas A, Garcia-Rodriguez LA, Arroyo MT et al:Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102:507-515, 2007
11) Ng FH, Wong Sy, Lam KF et al:Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138:82-88, 2010
12) Sugano K, Matsumoto Y, Itabashi T et al:Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 46:724-735, 2011
13) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease:a meta-analysis. Lancet 359:14-22, 2002
14) Chan FK, Chung SC, Suen BY et al:Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973, 2001
15) Lai KC, Lam SK, Chu KM et al:Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346:2033-2038, 2002
16) Vergara M, Catalan M, Gisbert JP et al:Meta-analysis:role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21:1411-1418, 2005
17) Silverstein FE, Faich G, Goldstein JL et al:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284:1247-1255, 2000
18) Chan FK, Wong VW, Suen BY et al:Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk:a double-blind, randomised trial. Lancet 369:1621-1626, 2007
19) Hernandez-Diaz S, Rodriguez LA:Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation:an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093-2099, 2000
20) Singh G:Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105:31S-38S, 1998

PART 5. NSAIDs潰瘍の保険診療と実地診療のためのQ & A

P.130 掲載の参考文献
1) 後藤信哉:動脈硬化/血栓性疾患ハンドブック. 医歯薬出版, 東京, 2009
2) 後藤信哉, 浅田祐士郎:血栓症-やさしく, くわしく, わかりやすく. 南江堂, 東京, 2006
4) Steg PG, Bhatt DL, Wilson PW et al:One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197-1206, 2007
5) Bhatt DL, Eagle KA, Ohman EM et al:Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350-1357, 2010
6) Ducrocq G, Wallace JS, Baron G et al:Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 31:1257-1265, 2010
7) 後藤信哉:抗血栓療法ハンドブック. 中外医学社, 東京, 2011
P.133 掲載の参考文献
1) Yang YX, Lewis JD, Epstein S et al:Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953, 2006

最近チェックした商品履歴

Loading...